Albiglutide (Tanzeum®), Dulaglutide (Trulicity®), Exenatide (Byetta®), exenatide extended release (Bydureon®, Bydureon® BCise), liraglutide (Victoza®), lixisenatide (Adlyxin®), and semaglutide (Ozempic®).


Indications for Prior Authorization:
  • Adjunctive therapy to improve glycemic control in type 2 diabetic patients who are compliant with metformin and have not achieved adequate glycemic control
  • Current A1c greater than 7 but less than 10 while compliant on oral therapy must be submitted for approval

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Treatment of Type 1 diabetes
  • Treatment of ketoacidosis
  • Appetite suppression or treatment of obesity

All of the following must be met as a condition(s) for coverage:

  • Diagnosis of Type 2 diabetes
  • Failure, as defined as an HbA1c > 7%, intolerance or contraindication to metformin at maximum effective therapeutic dose of 1,500 mg/day or maximum tolerated does unless contraindicated.  Unless contraindicated, member must currently adhere to maximal tolerated dose of metformin
    • An A1c level must be taken after a minimum of 3 months since last metformin dose change with confirmation in the pharmacy claims adjudication history of patient compliance with the treatment regimen
  • Concurrent administration with any dipeptidyl peptidase-4 inhibitor is not approvable
  • Exenatide (Byetta), Exenatide Extended-Release (Bydureon, Bydureon BCise) and Liraglutide (Victoza) are the preferred agents
  • Albiglutide (Tanzeum) is being discontinued from the market by the manufacturer effective July 2018.

albiglutide (Tanzeum)


  • Usual dosing:  30 mg SubQ once weekly.
  • May increase to 50 mg SubQ once weekly for inadequate glycemic response

dulaglutide (Trulicity)


  • Initial Dosing:  0.75 mg SubQ once weekly
  • May increase to 1.5 mg once weekly if inadequate glycemic response
  • Maximum dose:  1.5 mg once weekly

exenatide (Byetta®)


  • Initiate at 5 mcg SubQ twice a day 60 minutes prior to morning and evening meals. If an inadequate response, then dose may be increased to 10 mcg twice a day after one month

exenatide extended release (Bydureon®, Bydureon® BCise™)


  • Inject 2 mg SubQ every week

liraglutide (Victoza®)


  • Type 2 diabetes mellitus:
  • Initial dosage:
    • 0.6 mg subcutaneously per day for 1 week.1
  • Dosage titration:
    • After 1 week at 0.6 mg/day subcutaneously, the dose should be increased to 1.2 mg. If the 1.2 mg dose does not result in acceptable glycemic control, the dose can be increased to 1.8 mg

lixisenatide (Adlyxin®)


  • Initial dosage:
    • 10 mcg once daily for 14 days
  • Dosage titration:
    • On day 15 increase to 20 mcg once daily.  Maintenace dose: 20mcg once daily

semaglutide (Ozempic®)


  • Initial dosage:
    • 0.25 mg once weekly for 4 weeks.  
  • Dosage titration:
    • Increase to 0.5 mg once weekly for at least 4 weeks; if further glycemic control is necessary, increase to a maximum of 1mg once weekly. 

Last review date: November 13, 2018

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar